Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

For decades, researchers have been looking for an effective weight-loss pill. But the recent success of glucagon-like peptide-1 (GLP-1) weight-loss injections has sparked new hope — especially for ...

Weight-loss injections have rapidly moved from specialist clinics to social media feeds and high-street pharmacies. Known as ...

Blockbuster weight-loss drugs are transforming the way we treat obesity. But while costly injectable versions remain out of reach for many, newly approved tablet forms are expected to significantly ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...

Hims & Hers on Saturday said it would stop offering its copycat Wegovy weight-loss pill. The decision comes after Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration threatened ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Eli Lilly (LLY) has built up its inventory for its experimental weight loss pill, orforglipron, as the Indiana-based pharma giant awaits a potential FDA approval for the oral GLP-1 drug over the ...

Feb 12 (Reuters) - Eli Lilly (LLY.N), opens new tab had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug ...

Novo Nordisk said Wednesday that demand for its Wegovy pill got off to a strong start after it launched in the U.S. in early January. By Jan. 23 — less than three weeks after it became available — ...